Article: Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleSequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess
AuthorsNg, FH2
Wong, WM1
Wong, BCY
Kng, C2
Wong, SY2
Lai, KC
Cheng, CS2
Yuen, WC2
Lam, SK
Lai, CL
Issue Date2002
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
CitationAlimentary Pharmacology And Therapeutics, 2002, v. 16 n. 6, p. 1083-1090 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2036.2002.01266.x
AbstractAim: Pyogenic liver abscesses result in substantial morbidity and mortality. Antimicrobial regimens using sequential intravenous/oral therapy may reduce the length of hospital stay. In this retrospective analysis, the efficacy of continuous intravenous antibiotic therapy (group I) vs. sequential intravenous/oral antibiotic therapy (group II) was studied in patients with pyogenic liver abscess. Methods: One hundred and twelve consecutive patients (55 in group I and 57 in group II) with pyogenic liver abscess were analysed. Clinical response, length of hospital stay and relapse rates were examined. Results: Group II had a significantly shorter duration of intravenous antibiotic treatment (3.2 weeks vs. 5.9 weeks, P < 0.01) and a shorter length of hospital stay (28 days vs, 42 days, P < 0.01) when compared to group I. Oral antibiotics were prescribed for a median duration of 2.9 weeks in group II after discharge. No relapse occurred within 6 weeks after the completion of treatment in both groups. The cost of therapy was significantly lower in group II than in group I by 33%. Conclusions: A sequential intravenous/oral antibiotic regime is a safe and effective treatment for pyogenic liver abscess. This reduces the cost of therapy and the length of hospital stay.
ISSN0269-2813
2011 Impact Factor: 3.769
2011 SCImago Journal Rankings: 0.338
DOIhttp://dx.doi.org/10.1046/j.1365-2036.2002.01266.x
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorNg, FH
dc.contributor.authorWong, WM
dc.contributor.authorWong, BCY
dc.contributor.authorKng, C
dc.contributor.authorWong, SY
dc.contributor.authorLai, KC
dc.contributor.authorCheng, CS
dc.contributor.authorYuen, WC
dc.contributor.authorLam, SK
dc.contributor.authorLai, CL
dc.date.accessioned2012-09-05T05:21:16Z
dc.date.available2012-09-05T05:21:16Z
dc.date.issued2002
dc.description.abstractAim: Pyogenic liver abscesses result in substantial morbidity and mortality. Antimicrobial regimens using sequential intravenous/oral therapy may reduce the length of hospital stay. In this retrospective analysis, the efficacy of continuous intravenous antibiotic therapy (group I) vs. sequential intravenous/oral antibiotic therapy (group II) was studied in patients with pyogenic liver abscess. Methods: One hundred and twelve consecutive patients (55 in group I and 57 in group II) with pyogenic liver abscess were analysed. Clinical response, length of hospital stay and relapse rates were examined. Results: Group II had a significantly shorter duration of intravenous antibiotic treatment (3.2 weeks vs. 5.9 weeks, P < 0.01) and a shorter length of hospital stay (28 days vs, 42 days, P < 0.01) when compared to group I. Oral antibiotics were prescribed for a median duration of 2.9 weeks in group II after discharge. No relapse occurred within 6 weeks after the completion of treatment in both groups. The cost of therapy was significantly lower in group II than in group I by 33%. Conclusions: A sequential intravenous/oral antibiotic regime is a safe and effective treatment for pyogenic liver abscess. This reduces the cost of therapy and the length of hospital stay.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2002, v. 16 n. 6, p. 1083-1090 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2036.2002.01266.x
dc.identifier.doihttp://dx.doi.org/10.1046/j.1365-2036.2002.01266.x
dc.identifier.epage1090
dc.identifier.hkuros66971
dc.identifier.isiWOS:000175838300006
dc.identifier.issn0269-2813
2011 Impact Factor: 3.769
2011 SCImago Journal Rankings: 0.338
dc.identifier.issue6
dc.identifier.scopuseid_2-s2.0-0035999139
dc.identifier.spage1083
dc.identifier.urihttp://hdl.handle.net/10722/162566
dc.identifier.volume16
dc.languageeng
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
dc.publisher.placeUnited Kingdom
dc.relation.ispartofAlimentary Pharmacology and Therapeutics
dc.relation.referencesReferences in Scopus
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.
dc.titleSequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Ruttonjee Hospital Hong Kong